OrbiMed Advisors GDRX Position
ExitedOrbiMed Advisors exited their position in GoodRx Holdings Inc. (GDRX) in Q4 2023, after holding the stock for 4 quarters.
The position was first reported in Q1 2023 and has been tracked across 4 quarterly 13F filings.
1 other tracked fund also holds GDRX.
About GoodRx Holdings Inc.
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Full company profile →Short Interest
9.5%
2.4 days to cover
OrbiMed Advisors GDRX Position History
Frequently Asked Questions
Does OrbiMed Advisors own GDRX?
No. OrbiMed Advisors exited their position in GoodRx Holdings Inc. (GDRX) in Q4 2023. They previously held the stock for 4 quarters.
How many hedge funds own GDRX?
1 specialist biotech hedge fund currently holds GDRX, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy GDRX?
OrbiMed Advisors's position in GDRX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's GDRX position increasing or decreasing?
OrbiMed Advisors completely exited their GDRX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GDRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →